Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CETP | P11597 | 3/20 | 0.43 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | CTRC | Q99895 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16177916 | 0.89 | CTSK (0.42) | CETPCNR2 | |
| SCHEMBL21695449 | 0.89 | CTSK (0.41) | TSHRCETPALDH1A1CYP3A4MAPK1 | |
| SCHEMBL9030758 | 0.87 | CETP (0.43) | CETPCSNK1ECTRCCNR2EPHX2 | |
| SCHEMBL16667474 | 0.87 | CETP (0.43) | CETPCSNK1ECTRCCNR2EPHX2 | |
| SCHEMBL9030769 | 0.87 | CETP (0.43) | CETPCSNK1ECTRCCNR2EPHX2 | |
| SCHEMBL11731022 | 0.86 | CETP (0.41) | TSHRCETPCSNK1ECTRCALDH1A1 | |
| SCHEMBL11731029 | 0.86 | CETP (0.41) | TSHRCETPCSNK1ECTRCALDH1A1 | |
| SCHEMBL28998085 | 0.85 | CETP (0.45) | CETPCSNK1ECTRCMAPK1CNR2 | |
| SCHEMBL3427566 | 0.83 | EPHX2 (0.44) | CETPFAAHALDH1A1CNR2EPHX2 | |
| SCHEMBL3427569 | 0.83 | EPHX2 (0.44) | CETPFAAHALDH1A1CNR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871179-B2 | Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130052129-A1 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | THE GENERAL HOSPITAL CORPORATION (US) | 2013-02-28 | — | — | US | disclosed |
| US-8309053-B2 | Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid | THE GENERAL HOSPITAL CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-8268291-B2 | Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid | THE GENERAL HOSPITAL CORPORATION (US) | 2012-09-18 | — | — | US | disclosed |
| US-7790142-B2 | Using a radiolabeled fatty acid analog such as endo-[18F] fluoro- or [123I]iodo-3,4-cyclopropylheptadecanoic acid localized in tissue of interest, imaging, determining blood flow rate | THE GENERAL HOSPITAL CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090156848-A1 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | THE GENERAL HOSPITAL CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
| US-7494642-B2 | Fatty acid derivatives; tissue-targeted therapy; tomography; cardiovascular disorders; liver disorders; kits | THE GENERAL HOSPITAL CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080214851-A1 | Synthesis of labeled fatty acid analogs for use in tomography | THE GENERAL HOSPITAL CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080213178-A1 | Using a radiolabeled fatty acid analog such as endo-[18F] fluoro- or [123I]iodo-3,4-cyclopropylheptadecanoic acid localized in tissue of interest, imaging, determining blood flow rate | THE GENERAL HOSPITAL CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214853-A1 | Labeled cycloalkylidene-containing fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart or tumor | THE GENERAL HOSPITAL CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080213173-A1 | Labeled fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart, liver, or tumor; endo-vinylic variants of cycloalkyl-substituted heptadecanoic acid for example | THE GENERAL HOSPITAL CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080206135-A1 | Using a radiolabeled fatty acid analog such as endo-[18F] fluoro- or [123I]iodo-3,4-cyclopropylheptadecanoic acid localized in tissue of interest, imaging, determining blood flow rate | THE GENERAL HOSPITAL CORPORATION (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1622602-B1 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | GEN HOSPITAL CORP (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20080095702-A1 | Labeled fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart, liver, or tumor | THE GENERAL HOSPITAL CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| EP-1622602-A4 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | GEN HOSPITAL CORP (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1622602-A2 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | THE GENERAL HOSPITAL CORPORATION (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040253177-A1 | Fatty acid derivatives; tissue-targeted therapy; tomography; cardiovascular disorders; liver disorders; kits | GENERAL HOSPITAL CORPORATION, THE | 2004-12-16 | — | — | US | disclosed |
| WO-2004093650-A2 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | THE GENERAL HOSPITAL CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052129-A1 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | FABP3, FABP1, SLC27A2 | TSHR 1308/4885CETP 707/4885FAAH 66/4885 |
| US-20080214851-A1 | Synthesis of labeled fatty acid analogs for use in tomography | FFAR4, FFAR3, FFAR2 | TSHR 1189/4885CETP 386/4885FAAH 51/4885 |
| US-20080214853-A1 | Labeled cycloalkylidene-containing fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart or tumor | FABP3, FFAR2, FFAR1 | TSHR 917/4885CETP 476/4885FAAH 44/4885 |
| US-20080206135-A1 | Using a radiolabeled fatty acid analog such as endo-[18F] fluoro- or [123I]iodo-3,4-cyclopropylheptadecanoic acid localized in tissue of interest, imaging, determining blood flow rate | FFAR3, FFAR2, FFAR1 | TSHR 1155/4885CETP 473/4885FAAH 13/4885 |
| US-20080213173-A1 | Labeled fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart, liver, or tumor; endo-vinylic variants of cycloalkyl-substituted heptadecanoic acid for example | FABP3, FABP1, FFAR2 | TSHR 1016/4885CETP 445/4885FAAH 62/4885 |
| US-20080095702-A1 | Labeled fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart, liver, or tumor | FABP3, FABP1, FFAR2 | TSHR 717/4885CETP 396/4885FAAH 77/4885 |
| US-20080213178-A1 | Using a radiolabeled fatty acid analog such as endo-[18F] fluoro- or [123I]iodo-3,4-cyclopropylheptadecanoic acid localized in tissue of interest, imaging, determining blood flow rate | FFAR3, FFAR2, FFAR1 | TSHR 1155/4885CETP 473/4885FAAH 13/4885 |
| US-20040253177-A1 | Fatty acid derivatives; tissue-targeted therapy; tomography; cardiovascular disorders; liver disorders; kits | FABP1, FABP3, FFAR2 | TSHR 793/4885CETP 118/4885FAAH 69/4885 |
| US-20090156848-A1 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | FABP3, FABP1, SLC27A2 | TSHR 1308/4885CETP 707/4885FAAH 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.